Floatz logo

TAMOXIFEN

Cancer of the Fallopian Tube

Nordic Society of Gynaecological Oncology - Clinical Trials UnitSmall moleculePhase 3Dormant
BB
68/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
55/ 100
Competitive Position
95/ 100

Competitive context

73 Active assets in the Cancer of the Fallopian Tube cohort.

Asset / SponsorPhaseRating
Carboplatin
Women's Hospital School Of Medicine Zhejiang University
Phase 3BBB
CIS-DIAMMINEDICHLOROPLATINUM II
Mayo Clinic
Phase 3BB
Cyclophosphamide
Mayo Clinic
Phase 2BB
Pembrolizumab
Roswell Park Cancer Institute
Phase 2BB
Olaparib
National Cancer Institute (NCI)
Phase 3BB

View all 50 →

Same molecule, other indications

TAMOXIFEN is also rated in:

estrogen-receptor positive breast cancerDormant
BBB
Indicative ·
77 / 100
View asset →
breast carcinomaDormant
BBB
Indicative ·
75 / 100
View asset →
invasive breast carcinomaDormant
BBB
Indicative ·
75 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →